Normal and tumor DNA samples of 35 patients with sporadic colorectal carcinoma were analyzed for microsatellite alterations at 12 markers linked to mismatch repair loci: hMLH1, hMSH2, hMSH3, hMSH6, hPMS1 and hPMS2. Remarkably, no correlation was observed between the replication error phenotype (RER ⍣ ) and allelic losses at these loci. Hemizygous deletions, seen in 6/35 (17%) informative cases at hMLH1, 4/27 (15%) at hMSH2/hMSH6 and 6/34 (18%) at hMSH3, were rarely found in RER ϩ tumors. Since mismatch repair protein components act in molecular complexes of defined stoichiometry we propose that hemizygous deletion of the corresponding loci may be involved in colorectal tumorigenesis through defects in cellular functions other than replication error correction. The analysis of the methylation status of the promoter region of hMLH1 revealed that methylation might be an important mechanism of this locus inactivation in RER ϩ sporadic colorectal cancer.
Introduction
Colorectal cancer is one of the most common forms of cancer in the western world. Its evolution is believed to involve multiple molecular steps through the accumulation of genetic alterations in oncogenes and tumor suppressor genes (1) . Most cases are sporadic, although dominant inheritance has been suggested in 15% of patients (2, 3) . In hereditary non-polyposis colorectal cancer (HNPCC), genetic predisposition was shown to be associated with germline mutations in the mismatch repair genes, hMSH2 (4, 5) , hMLH1 (6, 7) , hMSH6 (8) , hPMS1 and hPMS2 (9) . As in tumor suppressor genes, the inactivation of mismatch repair genes seems to occur in two steps: the first mutation, either somatic (sporadic cancer) or germinal (hereditary cancer), is followed by another somatic event. The latter can involve loss of heterozygosity (LOH) as already reported for hMLH1 in HNPCC and in sporadic cases (10) (11) (12) .
The absence of mismatch repair leads to a deficiency in the correction of replication errors (RER), readily detected as microsatellite instability (RER ϩ phenotype) in tumor cells. The RER ϩ phenotype, which is characteristic of 92% of HNPCC tumors (13) , was observed in 12-28% of sporadic colorectal cancers (14) (15) (16) (17) . However, only a subset of the RER ϩ sporadic cases was seen associated with mutations in either hMSH2, hMLH1, hPMS1 or hPMS2 (18) (19) (20) , which suggests a contribution of mutations at other loci (21) . Alternative mechanisms of gene inactivation, such as promoter methylation (22) or differential splicing (23) , should also be considered.
In this study, aimed at sporadic colorectal cancer, we used di-and tetranucleotide markers to simultaneously analyze microsatellite instability and LOH at six mismatch repair loci. Although we find no evidence of hemizygous loss of these genes in RER ϩ tumors, alternative mechanism such as hypermethylation appear to play an important role in hMLH1 inactivation.
Materials and methods
Paired normal and tumor samples were obtained from 35 colorectal cancer patients who underwent surgery at the Hôtel-Dieu Hospital in Montreal (n ϭ 29) and the Victoria Hospital in Prince Albert (n ϭ 6). This is an unselected group of apparently sporadic cases with limited clinical information. DNA was isolated by a standard procedure using digestion with proteinase K and phenol-chloroform extractions.
Matched pairs of normal/tumor DNAs were allelotyped as described by Baccichet et al. (24) at the following loci: D3S1745, D3S1561, D3S1611, D3S1298 linked to hMLH1 (3p21); D5S398, D5S491 linked to hMSH3 (5q11-q13); D2S391, D2S288 linked to hMSH2/hMSH6 (2p16); D2S318, D2S118 linked to hPMS1 (2q32); and D7S531, D7S517 linked to hPMS2 (7p22). The chromosomal assignment of the genes and microsatellites was performed by integrating genetic, radiation hybrid and STS/YAC data from several sources (25) (26) (27) . The change in size of one or both microsatellite alleles in tumor cells was considered as instability, whereas the loss or significant reduction in intensity of one allele in tumor samples compared with the paired normal DNA revealed LOH. Only the informative (heterozygous) loci were included in the estimation of LOH frequency.
The methylation status of the hMLH1 promoter was tested using a modification of the assay of Kane et al. (22) . Genomic DNA from patients (10 ng) that contained an internal control DNA (0.1 pg of a 3.3 kb plasmid construct with 0.3 kb human insert) were digested for 16 h using either 12 U of HpaII or 32 U of MspI. The cleavage at the hMLH1 promoter region was examined by PCR as described (22) .
Results
The allelotyping revealed LOH in 15 of the 35 (43%) tumors analyzed, in at least one of the 12 microsatellite loci tested ( Figure 1 , Table I ). Ten tumors (29%) displayed instability ( Figure 2 ) in at least one of these markers (Table II) , but only four (11.4%) that were unstable at two or more loci were classified RER ϩ . Interestingly, in these four RER ϩ tumors, seven or more of the 12 microsatellites tested were unstable (Table II) , making the separation between RER ϩ and RERtumors very distinct.
Six of the patients (17%) exhibited LOH at the hMLH1 region (Table I) including the intragenic marker D3S1611 (7). None of the tumors with LOH at hMLH1 displayed instability at more than one microsatellite (Tables II and III) , which suggests no correlation between the RER ϩ phenotype and LOH. Furthermore, the SSCP analysis (not shown) of tumors with LOH failed to detect any mutation in the 19 exons of the remaining hMLH1 allele. The markers linked to hMSH2/hMSH6 and hMSH3 were hemizygously deleted in tumor cells in four of the 27 cases and in six of the 34 cases, respectively (Table I) . Patient 67 was deleted at both regions. In one RER ϩ tumor (patient 29), LOH at the hMSH2/hMSH6 region, seen only at one microsatellite (Table II) , could be a false positive since here the allelic instability could produce a pattern of an allelic loss. None of the other patients with LOH at either hMSH2/hMSH6 or hMSH3 had RER ϩ tumors (Tables II and III) . Presumably, few allelic losses at hPMS2 and hPMS1 reflect the background level of LOHs in cancer cells rather than a specific effect (28) . One of the RER ϩ tumors (case 21) was associated with LOH at hPMS2 (Tables II and III) . Taken together, our results indicate an absence of correlation (P ϭ 1, Fisher's test) between LOH at hMLH1, hMSH2/hMSH6 and hMSH3 and the RER ϩ phenotype observed in this group of sporadic colorectal cancer patients (Table III) .
The absence of mutations detectable by SSCP among hMLH1 exons in RER ϩ tumors prompted us to investigate the methylation status of this gene promoter. The promoter segment (positions -650 to -67), containing four HpaII/MspI sites, was examined for CpG methylation in normal and tumor DNA. Three RER ϩ tumor samples (cases 13, 29 and 41) were resistant to HpaII digestion and sensitive to MspI digestion, whereas the corresponding normal DNAs were sensitive to both HpaII and MspI digestions (Figure 3a ). This contrasts with 11 tumor DNAs that included samples from the hemizygously deleted hMLH1 patients (Figure 3b ) and five other RER -tumors (data not shown) with instability at only one microsatellite (Table  II) . These were sensitive to digestion with both restriction enzymes, which indicates no methylation. It appears that promoter methylation could be a preponderant mechanism of hMLH1 inactivation in sporadic RER ϩ colorectal cancer.
Discussion
Thirty-five sporadic colorectal carcinomas were investigated for microsatellite alterations in order to determine the relationship between LOH at mismatch repair loci and the RER ϩ Table II ). hMSH2 and hMSH6 are located within a 1 Mb interval (18) .
phenotype. Allelic losses were found at hMSH2/hMSH6, hMLH1 and at hMSH3. We believe this is the first report of LOH at hMSH3 in colorectal carcinoma. LOH in the hMSH3 region was observed earlier in lung and breast carcinomas (29, 30) , which suggests its involvement in tumorigenesis. A relatively high level of allelic losses (16%) was also observed at hMSH2/hMSH6 whereas only a slight excess (6-9%) of hemizygous deletions in that region over the background level had been reported earlier (10, 12) . This difference can be related to the sets of markers assayed. For instance, D2S391 and D2S288, which are located at zero recombination fraction (0 cM) from hMSH2 (5), revealed LOH efficiently (10), whereas D2S123 (located~3 cM from hMSH2) was rarely affected by LOH (10, 12, 14) . The incidence of deletion at hMLH1 (17%) is similar to that reported in sporadic and hereditary colorectal cancers (10) (11) (12) . This was except for lung and breast cancer, where this region was deleted in almost half of cases (29, 30) , making it one of the most frequent genetic rearrangements in these neoplasias.
The RER ϩ phenotype was observed in 11% of tumors, which is consistent with earlier reports (14) (15) (16) (17) . However, 
Ϫ , no microsatellite instability detected; ϩ, microsatellite instability. a The 25 others tumors did not show instability at any of the 12 analyzed microsatellite markers. b Tumors considered as RER ϩ . 
a Only informative cases were included in the calculation.
none of the four RER ϩ tumors was deleted at hMLH1 or hMSH3. In hMSH2/hMSH6, the evidence is weak, with LOH in a single patient at only one of the linked markers. The absence of correlation between RER ϩ and LOH at mismatch repair genes (Table III) corroborates our observations with lung and breast cancers (29, 30) . This is in contrast to Tomlinson et al. (12) , who reported LOH at hMLH1 in 41% of sporadic RER ϩ colorectal cancers compared with 16% in the RERcancers. However, in that study the definition of the RER ϩ phenotype was less stringent than here, which substantially changes their inclusion criteria for their group of patients thus making these analyses effectively incomparable. This illustrates well the need for uniform inclusion criteria. The SSCP analysis of hMLH1 exons in patients hemizygous for this locus failed to reveal any mutation, which suggests that the non-deleted copy of this gene remained intact. If the non-deleted hMLH1, hMSH2 or hMSH3 alleles are active it explains the absence of the RER ϩ phenotype. Additional evidence is required to decide whether hemizygous deletions at mismatch repair loci promote cancer progression or whether the observed LOHs indicate only the linkage with as yet unknown tumor suppressor genes. However, it is also possible that a gene dosage effect that affects the stoichiometry and the activity of the heteromolecular mismatch repair complex may be sufficient to promote cancer by impairing functions other than the correction of replication errors. Mismatch repair proteins are known to be involved in a variety of vital cellular functions, such as homologous recombination (31, 32) , cell cycle checkpoint control (33) , chromosomal synapsis (34), both male and female fertility (34, 35) , transcription-coupled nucleotide excision repair (36) , the recognition of the DNA damage and/or in the signaling pathway contributing to the generation of apoptotic cells (37) . Interestingly, DeWeese et al. (38) reported that mammalian cells homozygous and hemizygous for disrupted hMSH2 alleles showed an increase in survival, a decrease in the apoptosis, an increase in the oxidative damage and an increase in the number of mutations as compared with the normal cells. A heterozygous mutation in hMSH2 in the human colorectal cancer cell line P8 was shown to reduce transcription-coupled repair (36) , which suggests that allelic deletion of hMLH1 and/or hMSH3 could have the same effect. In other words, we propose that a subtle defect in the repair of DNA damage, which is less likely to be lethal to the affected cells, could have a profound impact on tumorigenesis and places the carrying individuals at increased cancer risk.
Hypermethylation of the hMLH1 promoter was correlated with a lack of hMLH1 expression (22) . Our demonstration that this promoter was methylated in most RER ϩ tumors further supports the notion that hypermethylation of hMLH1 CpG island might be frequently associated with the inactivation of mismatch repair in RER ϩ tumors (22, 39, 40) . This mechanism could explain why not all of the tumors that lacked expression of hMLH1 or hMSH2 protein had identifiable mutations at these loci (22, 41) . The involvement of an aberrant methylation in carcinogenesis was also reported for growth regulatory genes (reviewed in ref. 42 ).
In conclusion, our analysis of sporadic colorectal cancers demonstrated that a majority of RER ϩ tumors displayed CpGmethylation of the hMLH1 promoter region, which suggests that this is a possible inactivation mechanism of mismatch repair genes. If this mechanism is indeed operating during cancer development it could have important clinical implications, which raises the possibility of reactivation of these silent genes with inhibitors of DNA methylation (42) . Our observation of LOH at mismatch repair loci such as hMLH1, hMSH3 and hMSH2/hMSH6 in the RER -cases points to the possibility that a dosage-effect that affects mismatch repair genes may promote cancer progression by impairing cellular functions other than the correction of replication errors, which leads to microsatellite instability.
